Navigation Links
ViroPharma to Discuss Commercialization and Launch of Cinryze(TM) on November 5, 2008
Date:10/30/2008

- Conference Call to Be Held at 4:00 P.M. Eastern Time -

EXTON, Pa., Oct. 30 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) will host a conference call and live audio webcast at 4:00 p.m. Eastern Time on Wednesday, November 5, 2008 to discuss the commercialization plans and launch of Cinryze C1 Inhibitor (human), which has been recently approved by the U.S. Food and Drug Administration for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE.

The live webcast of the conference call will be accessible via ViroPharma's corporate website at http://www.viropharma.com. An audio archive will be available at the same address until November 20, 2008. To participate in the conference call, please dial (877) 366-0713 (domestic) and (302) 607-2000 (international). After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R) (vancomycin hydrochloride capsules, USP), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains, and Cinryze(TM) (C1 inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, http://www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. ViroPharma Incorporated Reports Third Quarter 2008 Financial Results
2. ViroPharma to Release 2008 Second Quarter Financial Results on July 30, 2008
3. ViroPharma Incorporated Reports First Quarter 2008 Financial Results
4. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results
5. Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma
6. ViroPharma Provides Update on Vancocin(R)
7. ViroPharma Augments Senior Management
8. ViroPharma to Present at the 26th Annual JP Morgan Healthcare Conference
9. ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM)
10. ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results
11. ViroPharma to Present at the UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... The 89th Academy Awards will be ... 2016 National Education Policy Center Bunkum Award. We invite you to enjoy our 11th ... year’s Bunkum winner is the Center for American Progress (CAP), for its report, Lessons ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... with a clinician-based audience, will be participating in Rare Disease Day events, hosted ... D.C. In addition, Rare Disease Report, a website, weekly e-newsletter and quarterly publication, ...
(Date:2/23/2017)... CA (PRWEB) , ... February 23, 2017 , ... Los ... two episodes of WE TV’s “Mama June: From Not to Hot,” which will begin ... notable, “Mama” June Shannon, known to millions from the 2012 reality television series, “Here ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, ... relations, content marketing, social media management, corporate communications, SEO and cause marketing, is ... and in nearby New Hampshire, Massachusetts and Canada, Rosica will focus on expanding ...
(Date:2/23/2017)... ... February 23, 2017 , ... On April 13, 2017, ... on “Doping in Sport: How the Culture Might Change,” in conjunction ... The symposium will be held at Pepperdine University in Malibu, California. , Sir ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , 23. Februar 2017 Im Rahmen ... eine nationale Wirtschaftszone in der südwestlichen chinesischen Provinz Guizhou, 2017 ... Errichtung einer Innovationsplattform aktiv an der Entwicklung einer eingebetteten Hightech-Schlüsselindustrie. ... Continue Reading ... ...
(Date:2/23/2017)... 23, 2017 AcelRx Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of innovative therapies for the ... will release fourth quarter and yearly financial results ... AcelRx management will host an investment-community conference call ... Time) on March 2 nd 2017 to ...
(Date:2/23/2017)... -- According to a new market research ... Analog), MRI (Closed, Open), Ultrasound, CT, Nuclear Imaging (SPECT, ... (Hospitals, Imaging Centers) - Global Forecast to 2021", published ... the forecast period of 2016 to 2021. The market ... at a CAGR of 6.6% from 2016 to 2021. ...
Breaking Medicine Technology: